6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the Month of May, 2008

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant’s name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x   Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨   No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_______________.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of  1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Lorus Therapeutics Inc.
Date: May 6, 2008	By:	/s/ “Elizabeth Williams”
		Elizabeth Williams
		Director of Finance and Controller

EXHIBIT INDEX

99.1 News Release dated May 6, 2008 - AMEX Accepts Lorus' Plan to Meet AMEX's Continued Listing Standards

EX-99.1

EXHIBIT 99.1

News release via Canada NewsWire, Toronto 416-863-9350

	    Attention Business Editors:
	    AMEX Accepts Lorus' Plan to Meet AMEX's Continued Listing Standards

	    TORONTO, May 6 /CNW/ - Lorus Therapeutics Inc. ("Lorus" or the "Company")
(TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the
research and development of pharmaceutical products and technologies for the
management of cancer, has received a notice from the American Stock Exchange
("AMEX") indicating that Amex has accepted Lorus' plan of compliance and
granted the Company an extension until no later than August 13, 2009 to regain
compliance with the AMEX's continued listing standards.
	    As previously disclosed, on February 19, 2008, the Company received
notice from the AMEX staff indicating that the Company was not in compliance
with the $6 million stockholder's equity threshold required for continued
listing under AMEX Company Guide Section 1003(a)(iii). The Company was
afforded the opportunity to submit a plan of compliance to the AMEX and on
March 11, 2008 presented its plan to the AMEX. On April 30, 2008 AMEX notified
the Company that it accepted the Company's plan of compliance and granted the
Company an extension until August 13, 2009 to regain compliance with the
continued listing standards.
	    The Company will be subject to periodic review by the AMEX during the
extension period. Continued listing on AMEX is dependent upon making progress
consistent with the plan or in regaining compliance with the continued listing
standards by the end of the extension period.

	    About Lorus

	    Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to capitalize on
its research, preclinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination with other
drugs, to successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto
Stock Exchange under the symbol LOR, and on the American Stock Exchange under
the symbol LRP.

	    Forward Looking Statements

	    This press release contains forward-looking statements within the meaning
of Canadian and U.S. securities laws. Such statements include, but are not
limited to, statements relating to: financings and corporate reorganizations,
the establishment of corporate alliances, the Company's plans, objectives,
expectations and intentions and other statements including words such as
"continue", "expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered
reasonable by us are inherently subject to significant business, economic,
competitive, political and social uncertainties and contingencies. Many
factors could cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements
described in this press release. Such expressed or implied forward looking
statements could include, among others: our ability to meet AMEX's continued
listing requirements; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports and annual
filings with Canadian securities regulators and the United States Securities
and Exchange Commission.
	    Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our filings
with Canadian securities regulators and the United States Securities and
Exchange Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described herein.
These forward-looking statements are made as of the date of this press release
and we do not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure you
that such statements will prove to be accurate as actual results and future
events could differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not guarantees of
future performance and accordingly investors are cautioned not to put undue
reliance on forward-looking statements due to the inherent uncertainty
therein.

	    Lorus Therapeutics Inc.'s recent press releases are available through its
website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please
go to www.Sedar.com. For SEDAR filings prior to July 10, 2007 you will find
these under the company profile for Global Summit Real Estate Inc. (Old
Lorus).

	    %SEDAR: 00025614E          %CIK: 0000882361

	    /For further information: Lorus Therapeutics Inc., Dr. Saeid Babaei,
(416) 798-1200 ext. 490, ir(at)lorusthera.com/
	    (LOR. LRP)

CO:  Lorus Therapeutics Inc.

CNW 07:30e 06-MAY-08